{
    "clinical_study": {
        "@rank": "21626", 
        "arm_group": [
            {
                "arm_group_label": "DA-6034 45mg", 
                "arm_group_type": "Experimental", 
                "description": "two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day."
            }, 
            {
                "arm_group_label": "DA-6034 90mg", 
                "arm_group_type": "Experimental", 
                "description": "two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day."
            }, 
            {
                "arm_group_label": "Rebamipide 300mg", 
                "arm_group_type": "Active Comparator", 
                "description": "two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, double-blinded, double-dummy, active-controlled, randomized, Phase\n      III clinical trial to evaluate the efficacy and safety of DA-6034 and to demonstrate the\n      non-inferiority of DA-6034 compared with Rebamipide in patients with acute or chronic\n      gastritis. Subjects will receive 45mg, 90mg of DA-6034 and 300mg of Rebamipide, two tablets,\n      three times a day for two weeks."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034", 
        "condition": [
            "Acute Gastritis", 
            "Chronic Gastritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastritis", 
                "Gastritis, Atrophic", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with acute gastritis or chronic gastritis\n\n          -  1 or more erosions found in the gastroscope examination\n\n          -  Age should be: 20\u2264age\u226475\n\n        Exclusion Criteria:\n\n          -  A patient with peptic ulcer and a gastroesophageal reflux disease.\n\n          -  Received a medication including non-steroid anti-inflammatory drug 2 weeks before the\n             initiation\n\n          -  Had a surgery regarding gastroesophageal\n\n          -  A patient with Zollinger-Ellison syndrome\n\n          -  Had a medical history of a malignant tumor\n\n          -  A patient who is currently taking anti-thrombotic drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "492", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813812", 
            "org_study_id": "DA6034_Gas_III (Version 4.3)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DA-6034 45mg", 
                    "DA-6034 90mg"
                ], 
                "intervention_name": "DA-6034", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rebamipide 300mg", 
                "intervention_name": "Rebamipide 300mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rebamipide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2013", 
        "location": {
            "contact": {
                "email": "snuhirb@gmail.com", 
                "last_name": "Hyun Chae Jung, M.D., Ph.D.", 
                "phone": "82-2-2072-0694"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis", 
        "overall_contact": {
            "email": "snuhirb@gmail.com", 
            "last_name": "Hyun Chae Jung, M.D., Ph.D.", 
            "phone": "82-2-2072-0694"
        }, 
        "overall_official": [
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Hyun Chae Jung, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Catholic University Yeouido St. Mary's Hopspital", 
                "last_name": "Soo Heon Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyungpook National University", 
                "last_name": "Seong Woo Jeon, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University", 
                "last_name": "Sang Woo Lee, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Bundang Hospital", 
                "last_name": "Dong Ho Lee, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "SMG-SNU Boramae Medical Center", 
                "last_name": "Kook Lae Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Soonchunhyang University Hospital", 
                "last_name": "Ju Yung Cho, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ajou University School of Medicine", 
                "last_name": "Ki Myeong Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Severance Hospital, Yonsei University", 
                "last_name": "Yongchan Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Sang Yong Seol, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Jeong Seop Moon, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Jong Sun Rew, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonbuk National University Hospital", 
                "last_name": "Soo Taek Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chosun University Hospital", 
                "last_name": "Chan Kook Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chung-Ang University Hospital", 
                "last_name": "Jae Gyu Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chungbuk National University", 
                "last_name": "Sei Jin Youn, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hallym University Medical Center", 
                "last_name": "Hak Yang Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanyang University", 
                "last_name": "Byung Chul Yoon, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wonkwang university Hospital", 
                "last_name": "Suck Chei Choi, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ewha Womans University Mokdong Hospital", 
                "last_name": "Ki Nam Shim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The scale is classified into 5 steps which are based on the severity of the improvement.\nEX) noticable improvement: 4->1, 3->1, slight improvement: 4->3, 3->2", 
            "measure": "The number of erosions comparing the before and after the administration. For example, if the number of the erosion is 0, the score is 1 (normal).", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813812"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The number of erosions diagnosed by the gastroscope", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "the example of the symptoms are:\nepigastralgia, heartburn, acid reflux, nausea, domperidone", 
                "measure": "The severity of the digestive symptoms (Scale of 1 to 5)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}